Product
Jardiance
Aliases
Jardiance film-coated tablets
Name
Jardiance
INN Name
Empagliflozin
FDA Approved
Yes
3 clinical trials
5 organizations
8 indications
1 document
Indication
Type 2 Diabetes MellitusIndication
PrediabetesIndication
WeightIndication
BodyIndication
Cardiovascular DiseasesIndication
Coronary Artery DiseaseIndication
AtherosclerosisIndication
Myocardial InfarctionClinical trial
An Open-label, Balanced, Randomized, Two Treatment, Two Sequence, Two Period, Two Way Cross-over, Single Oral Dose Bioequivalence Study of Empagliflozin 25 mg Film Coated Tablets of Humanis, Turkey and Jardiance (Empagliflozin) 25 mg Film-coated Tablets of Boehringer Ingelheim International GmbH, Germany in Normal, Healthy, Adult, Human Subjects Under Fasting ConditionStatus: Completed, Estimated PCD: 2023-08-27
Clinical trial
Pioneering and Affordable Strategies to Prevent Progression of Prediabetes, Obesity and CV Risk in HispanicsStatus: Recruiting, Estimated PCD: 2027-07-01
Clinical trial
Aggressive Risk-Prevention Therapies for Coronary Atherosclerotic Plaque (ART-CAP)Status: Recruiting, Estimated PCD: 2029-01-31
Document
DailyMed Label: JardianceOrganization
Aphena Pharma Solutions - Tennessee, LLCOrganization
A-S Medication SolutionsOrganization
Praxis, LLCOrganization
Aphena Pharma Solutions - Tennessee, LLC Organization
Boehringer Ingelheim Pharmaceuticals, Inc.